LFMD LIFEMD INC

LifeMD, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 10, 2022

LifeMD, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 10, 2022

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced that it will report its financial results for the third quarter ended September 30, 2022 after the market close on Thursday, November 10, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

Conference Call & Webcast Details:
Date:Thursday, November 10th
Time:4:30pm ET
Toll Free:1-800-218-2154
International:1-720-543-0214 
Conference ID:1668855
Webcast:/starthere.jsp?ei=1580105&tp_key=82ee8cfb68

About LifeMD

LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Company Contact

LifeMD, Inc.

Marc Benathen, CFO



EN
26/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIFEMD INC

 PRESS RELEASE

LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bund...

LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy® Bundled Offer Includes Wegovy® at $199 and LifeMD’s Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes both the medication and access to LifeMD’s virtual weight management program. As part of it...

 PRESS RELEASE

LifeMD to Participate in Three Investor Conferences During May

LifeMD to Participate in Three Investor Conferences During May NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will be holding one-on-one meetings with investors.B. Riley Securities 25th Annual Institutional Investor Conference, May 21-22 at the Ritz-Carlton in Marina Del Rey. Management will be presenting...

 PRESS RELEASE

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Gu...

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70%Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago periodTelehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago periodGAAP net income of $0.6 million or $0.01 per diluted share, delivering first-ever quarter of positive GAAP EPSRaising full-year 2025 guidance for both total revenues and adjusted EBITDA, reflecting strong year-to-date performance in telehealth ...

 PRESS RELEASE

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash...

LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform. LifeMD’s weight management program is one of the fastest-growing cash-pay offerings in the country, deliver...

 PRESS RELEASE

LifeMD to Report First Quarter 2025 Financial Results on May 6

LifeMD to Report First Quarter 2025 Financial Results on May 6 NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:   ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch